Fortrea Holdings Inc. (FTRE) FY2025 10-K Annual Report
Fortrea Holdings Inc. (FTRE) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Fortrea Holdings Inc. FY2025 10-K Analysis
Business Overview
- • Core business model: global contract research organization (CRO) providing clinical trial management and consulting services across 20+ therapeutic areas
- • Strategic shift: spun off from Labcorp Holdings on June 29, 2023, becoming standalone publicly traded company
- • Notable transaction: sold Enabling Services Segment (Fortrea Patient Access Inc. and Endpoint Clinical, Inc.) to Arsenal Capital Partners in Q2 2024
- • Workforce scale: approximately 14,300 employees operating in about 100 countries
- • Reporting structure: operates under one clinical services segment post-separation
Management Discussion & Analysis
- • Revenue $2,723.4M, up 1.0% YoY vs $2,696.4M in 2024; organic growth 0.8%, FX benefit 0.2%
- • Operating costs: direct costs 81.5% of revenue vs 80.2% in 2024; SG&A down 18.6% to $456.4M from $560.7M
- • Segment impairment: Clinical Development goodwill impairment $797.9M in 2025, none in 2024
- • Cash flow: operating cash $113.5M vs $262.8M in 2024; capital expenditures $25.2M vs $25.5M; repurchased $75.7M notes in 2025
- • Outlook: monitors new OECD global minimum tax, no Pillar Two tax accrued in 2025; believes existing cash and credit suffice for 12 months operations
Risk Factors
- • FTC scrutiny under Transition Services Agreement post-Spin from Labcorp completed June 30, 2023, affecting centralized function costs allocation
- • Revenue exposure from geopolitical risks in ~100 countries with operations, disrupting clinical trials and regulatory approvals
- • Post-sale of Enabling Services Segment assets for $340M in Q2 2024, operational shift risk in transition service dependencies
- • Market competition risk from larger CROs like IQVIA and ICON impacting contract awards in key therapeutic areas
- • Financial risk from potential backlog cancellations despite $7.7B backlog as of December 31, 2025, with contracts having 30-90 day termination notice
Fortrea Holdings Inc. FY2025 Key Financial MetricsXBRL
Revenue
$2.7B
▲ +1.0% YoY
Net Income
-$986M
▼ -200.2% YoY
Operating Margin
-32.0%
▼ -2604bp YoY
Net Margin
-36.2%
▼ -2403bp YoY
ROE
-175.0%
▼ -15090bp YoY
Total Assets
$2.7B
▼ -24.1% YoY
EPS (Diluted)
$-10.81
▼ -194.6% YoY
Operating Cash Flow
$114M
▼ -56.8% YoY
Source: XBRL data from Fortrea Holdings Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Fortrea Holdings Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.